Dendritic cells (DCs) contribute to psoriasis pathogenesis. In a mouse model of imiquimod-induced psoriasiform skin inflammation, we found that p38 activity in Langerhans cells (LCs), a skin-resident subset of DCs, promoted the generation of T cells that produce IL-17, a proinflammatory cytokine that is implicated in autoimmune disease. Deletion of p38 in LCs, but not in other skin or circulating DC subsets or T cells, decreased T cell-mediated psoriasiform skin inflammation in mice. The activity of p38 in LCs specifically promoted IL-17 production from  and CD4 + T cells by increasing the abundance of IL-23 and IL-6, two cytokines that stimulate IL-17 secretion. Inhibition of p38 activity through either pharmacological inhibition or genetic deletion also reduced the severity of established psoriasiform skin inflammation. Together, our findings indicate a critical role for p38 signaling in LCs in promoting inflammatory responses in the skin and suggest that targeting p38 signaling in LCs may offer an effective therapeutic approach to treat psoriasis.
INTRODUCTION
Psoriasis is a common chronic inflammatory skin disease characterized by epidermal hyperplasia, erythematous plaque formation, and the inflammatory cell infiltration in the dermis and epidermis (1, 2) . Psoriasis is traditionally regarded as a local skin disease, but it is also associated with many systemic inflammatory diseases, such as diabetes and cardiovascular disease (3) . The etiology and pathogenesis of psoriasis are not fully understood, and accumulating evidence indicates that immune dysfunction plays pivotal roles in disease development (3, 4) . Psoriasis was initially classified as a disease mediated by the T helper type 1 (T H 1) cell response; however, cytokines released by interleukin-17 (IL-17)-producing T cells such as IL-17, tumor necrosis factor- (TNF), IL-23, and IL-22 appear to be critical for the development of psoriasis (3, (5) (6) (7) . Many of these cytokines are increased in psoriasis skin lesions (2, 8) , and many psoriasis patients have been effectively treated by using a new generation of drugs that selectively target TNF, IL-23, and IL-17 (9) . Although these cytokine antagonists provide higher efficacy, they can cause adverse side effects, such as increased risk of serious infection, cardiovascular disorders, and cancer development in psoriasis patients (10) . The TNF antagonist paradoxically induces new onset psoriasis or aggravates preexisting quiescent psoriatic disease by an unknown mechanism (11) . Moreover, these antagonist treatments are costly, and the responses are variable between different psoriasis patients (10) . Thus, therapeutic responses could be improved by characterization of the upstream cellular and molecular mechanisms that regulate generation of IL-17-producing T cells during psoriasis pathogenesis.
Dendritic cells (DCs) are the key sentinels of the immune system that bridge innate and adaptive immunity (12) and are critical for the development of psoriasis (13) . DCs are a highly heterogeneous population, and different tissues have different DC subsets with different functions (14) . Although much effort has been made to identify the precise taxonomy for skin DCs, the current classification for skin DC subsets is still somewhat complicated. There are at least three subsets of DCs in the steady-state human and mouse skin: epidermal Langerhans cells (LCs), dermal myeloid DCs (dDCs), and plasmacytoid DCs (pDCs) (15, 16) . According to their surface expression of langerin, mouse dDCs can be further divided into langerin + dDCs and langerin − dDCs (17) . Under steady state, langerin + dDCs are recruited from the blood to the dermis as well as capture tissue antigens and present these antigens to naïve T cells in the draining lymph nodes (DLNs) (17) .
In an imiquimod (IMQ)-induced psoriasis-like dermatitis (18) , IL-23 produced by either langerin − dDCs or LCs drives psoriatic plaque formation in mice (19, 20) . Moreover, in an IL-23-induced psoriasis-like mouse skin inflammation (21) , monocyte-derived inflammatory LCs and dDCs mediate the disease pathogenesis (22) . DC-specific deletion of ABIN-1 (A20 binding and inhibitor of nuclear factor B 1) restricts Toll-like receptor-induced IL-23 production and protects mice from IMQ-induced psoriasis (23) . IL-36 mediates the DC-keratinocyte (KC) cross-talk in an IMQ-induced psoriasiform dermatitis by regulating the IL-23/IL-17/IL-22 pathway, but the in vivo cellular source of IL-36 in psoriasis pathogenesis still needs to be clar ified (24) . In addition, retinoic acid-inducible gene I (RIG-1)-antiviral signaling drives endogenous IL-23 production in DCs to further promote psoriasislike disease (25) . Thus, despite strong evidence implicating DCs in psoriasis, the intracellular signaling pathways that regulate proinflammatory cytokines in psoriasis pathogenesis remains to be established.
Increased activity of p38 mitogen-activated protein kinase, a central regulator of inflammatory responses, is associated with susceptibility to psoriasis in humans (26) and is characteristic of psoriatic skin lesions (27) . p38 activity is also increased in KCs stimulated by stress stimuli, such as cytokines and ultraviolet irradia tion (28) . These findings indicate that targeting p38 could be a promising strategy to treat psoriasis (29) . Un fortunately, p38 inhibitors have not shown efficacy in the treatment of psoriasis, and many have been withdrawn from clinical trials because of adverse side effects (28) . Thus, it would be useful to define the cell types in which p38 is active in psoriasis.
Using a combination of genetic and molecular approaches, we report here that p38 deletion in LCs, but not in other DC subsets or T cells, reduced IMQ-induced psoriasiform skin inflammation. Mice with p38-deficient LCs produced much less IL-23 and IL-6 in response to IMQ treatment. Consequently, when chal lenged with IMQ, mice with a DC-specific deficiency in p38 showed reduced IL-17 production from  and CD4 + T cells. p38 signaling in LCs specifically promoted IL-17 production in  and CD4 + T cells through secretion of IL-23 and/or IL-6. However, p38 signaling in LCs was dispensable for the generation of interferon- (IFN)-, IL-4-, and Foxp3-expressing T cells. Intradermal injection of IL-23 restored the skin in flammation and proinflammatory cytokine ex pression in mice lacking p38 in DCs. In contrast, IL-6 injection partially restored skin inflammation and proinflammatory cytokine expression. Inhibition of p38 activity also reduced the severity of an established psoriasiform skin inflammation. Thus, this study links p38 signaling in LCs and IL-23 or IL-6 with IL-17 produc tion from  and CD4 + T cells, and it provides cellular and molecular mechanisms by which p38 regulates susceptibility to psoriasis.
RESULTS

Deletion of p38 in DCs ameliorates IMQ-induced psoriasiform skin disease in mice
In the IMQ-induced mouse psoriasiform skin dis ease model (18) , p38 activity in CD45 + leukocytes was higher in IMQtreated mouse skin than in control creamtreated mouse skin (Fig. 1A) . Because p38 Tamoxifen-pretreated WT and p38 CreER mice were topically treated with IMQ for six consecutive days.
Change in ear thickness (left) and disease severity score (right) were recorded (B) (n = 5 mice per group). Histopathological changes in skin tissue of WT (left) and p38 CreER (middle) mice were examined by hematoxylin and eosin (H&E) staining (n = 3 mice per group), and the marked area was magnified (right) (C). Scale bars, 200 m. (D) p-p38 in skin dendritic cells (DCs) was analyzed by flow cytometry in WT mice topically treated with control or IMQ-containing cream for two consecutive days (n = 6 mice per group). (E to J) WT and p38 DC mice were treated with IMQ for six consecutive days.
Change in ear thickness (left) and disease severity score (right) (E) (n = 5 mice per group), representative images of H&E staining of skin sections (n = 3 mice per group) (F), the percentages (G) and cell numbers (H) of neutrophils and macrophages in the epidermis (n = 4 mice per group), and the percentages (I) and cell numbers (J) of neutrophils and macrophages in the dermis (n = 4 mice per group). Scale bars, 200 m. Two-sided Student's t tests [right panels of (A), CreER mice" here, as described in our previous study (30) ] to determine the role of p38 in psoriasis pathogenesis and detected efficient deletion of p38 in skin tissue ( fig. S1A ). We explored the development of IMQ-induced psoriasiform skin in flammation in wildtype (WT) and p38
CreER mice, which were pretreated with tamoxifen to acutely delete p38 in skin tissue. We found that p38
CreER mice had reduced psoriatic symptom severity than WT mice, including ear swelling, epidermal hyperplasia, and skin inflammatory cell infiltration (Fig. 1, B and C) , suggesting that p38 signaling could promote the development of IMQ-induced psoriasiform skin inflammation.
Consistent with the role of DCs in psoriasis development (13) , IMQ-treated mouse skin had an increased percentage and number of DCs than control cream-treated skin ( fig. S1B ). In addition, p38 activity was higher in IMQtreated skin DCs (Fig. 1D) , suggesting that p38 signaling in DCs might play a pivotal role in the immune mechanisms during psoriasis development. To delineate the specific role of DC-intrinsic p38 signaling in psoriasis pathogenesis, we generated Mapk14 fl/fl CD11c-Cre mice [referred to as "p38 DC mice" here (30) ]. We observed efficient deletion of p38 in skin DCs ( fig. S1C ), which did not affect the percentages or activation status of DCs in either the epidermis or dermis ( fig. S2, A and B) . When treated with IMQ-containing cream, p38 DC mice had much less ear swelling and reduced composite psoriasis score than WT mice (Fig. 1E) . Histological analysis showed that the skin of p38 DC mice had less epidermal hyperplasia and inflammation (Fig. 1F) . Flow cytometry analysis showed that the infiltration of neutrophils and macrophages in the skin was increased after IMQ treatment ( fig. S3, A and B) . However, infiltration of neutrophils and macrophages into the epidermis and dermis was reduced in p38
DC mice (Fig. 1, G to J) . Notably, the percentages and cell numbers of LCs, CD4 + T cells, and  T cells, which are key producers of IL-17 during psoriasis, were comparable in the epidermis of IMQ-treated WT and p38 DC mice ( fig. S3, C and D) . Furthermore, there were no significant differences in neutrophil or macrophage numbers in the spleens of IMQ-treated WT and p38 DC mice ( fig. S3, E and F) . Collectively, these findings implicate a key role for DC-mediated p38 signaling in IMQ-induced psoriatic skin disease.
p38 activity in DCs regulates the generation of IL-17-producing T cells in the skin
Consistent with the critical role of IL-17-producing T cell-mediated inflammatory responses in psoriatic disease pathogenesis (3), the skin tissues from IMQ-treated p38 DC mice had lower expression of various related cytokine and chemokine mRNAs, such as Il17a, Tnfa, Il6, Il1b, Il23a, Csf2, and Cxcl1 ( Fig. 2A) . However, expression of Ifng, Il12a, Il4, Il10, Tgfb1, and Foxp3 was similar to that in WT mice ( Fig. 2A) . Although IL-22 plays an essential role in inflammatory skin disorders, including psoriasis (31) (32) (33) (34) , the expression of Il22 mRNA was comparable between WT and p38 DC mice ( Fig. 2A) . Moreover, certain genes encoding antimicrobial peptides such as S100a7a and S100a8, and genes responsible for KC proliferation including Krt16 and Krt17, were also significantly decreased in p38 DC mice ( Fig DC chimeras showed de creased ear thickness and composite psoriasis scores ( Fig. 3A and  fig. S7A ). Histological analysis showed that the skin of WT→p38 DC chimeras had substantially less epidermal hyperplasia and inflammation (Fig. 3B) . Flow cyto metry analysis showed that WT→p38 DC chimeras had diminished infiltration of neutrophils into the epidermis and dermis ( Fig. 3C and fig. S7B ). Intracellular staining also showed lower IL-17 production from  and CD4 + T cells in the DLNs of WT→p38 DC chimeras than did those from WT→WT chimeras ( Fig. 3D and fig. S7C ).
More over, skin samples from WT→p38 DC chimeras exhibited lower expression of Il17a, Tnfa, Il6, Il1b, and Cxcl1 mRNA expression than WT→WT chimeras (Fig. 3E) . Because LCs are resistant to x-ray irradiation (35) and both WT→WT and WT→p38 DC chimeras contained the same dDC and circulating DC subsets but different LCs, these results indicate that p38 signaling in LCs is important for IMQinduced psoriasiform skin inflammation.
When transplanting WT or p38 DC BM cells into x-ray-irradiated WT mice, we found that both IMQ-treated WT→WT and p38 DC →WT chimeras had comparable ear thickness and com posite psoriasis score ( Fig. 3A and fig. S7A ), histological changes ( Fig. 3B) , as well as similar infiltration of neutrophils into the epidermis and dermis ( Fig. 3C and fig. S7B ). The IL-17 production from  and CD4 + T cells in the DLNs was comparable (Fig. 3D and fig.  S7C ). Moreover, mRNA expression of Il17a, Tnfa, Il6, Il1b, and Cxcl1 was comparable between WT→WT and p38 DC →WT chimeras (Fig. 3E) . In addi tion, we found that WT→p38
DC and p38
DC chimeras had comparable skin inflammation and cyto kine production upon IMQ treatment (Fig. 3 , A to E, and fig. S7 , A to C). Thus, our results clearly show that p38 activity in host radioresistant LCs, but not in dDCs, is important for the generation of IL-17-producing T cells and the pathogenesis of psoriasis.
Signaling through p38 in LCs promotes IL-17-producing T cell generation and psoriasis pathogenesis by regulating the expression of IL-23 and IL-6
To assess whether p38 signaling in LCs stimulates T cells to produce IL-17, we cultured LCs from WT and p38 DC mice with  T cells in the presence of R848 for 48 hours.  T cells co cultured with p38 DC LCs produced significantly less IL-17 than did those cocultured with WT LCs (Fig. 4A) . To determine whether p38 mediates LC-T cell cross-talk by driving the lineage dif ferentia tion of antigen-specific naïve precursors, we cultured naïve CD4 + transgenic T cells specific for ovalbumin (OT-II) together with LCs isolated from WT and p38 DC mice in the presence of cognate antigen and R848 for 5 days. Fewer T cells cocultured with p38
DC LCs developed into IL-17 + cells than did those cocultured with WT LCs (Fig. 4B) . This effect was associated with lower Il17a mRNA expression in T cells activated by R848-pulsed p38
DC LCs, but comparable mRNA expression of Ifng, Il4, and Foxp3 ( fig. S8A ). These results indicate that p38 in LCs stimulates IL-17 production in T cells in vitro.
Next, we explored the molecular mechanisms by which p38 acted in LCs to promote IL-17-producing T cell development. WT and p38 DC mice expressed comparable costimulatory molecules, such as CD40, CD80, and CD86 in LCs upon IMQ treatment ( fig. S8B ). To determine whether p38 signaling in LCs regulates the expression of cytokines that biases IL-17-producing T cell development, we stim ulated LCs from WT and p38 DC mice with R848 for either 5 or 24 hours. Among the cytokines that potentiate IL-17-producing T cell differentiation, the expression of IL-6, IL-1, and IL-23 in LCs was lower in p38 DC mice than that in WT mice at both mRNA and protein levels (Fig. 4, C and D, and fig.  S8C ), but the mRNA levels of Il12a, Il27, and Tgfb1 and the protein level of TNF were comparable in LCs from WT and p38 DC mice (Fig. 4, C and D) . To identify the cytokine lost in p38
DC
LCs that was responsible for reduced T cell IL-17 production, we added back recombinant IL-23, IL-1, or IL-6 to LC- T cell cocultures. The addition of IL-23 to p38
DC LC- T cell cocultures completely restored the defective IL-17 production from  T cells, whereas the addition of IL-1 or IL-6 partially or did not restore the defective IL-17 production (Fig. 4E) . In LC-CD4 + T cell cocultures, we found that addition of IL-23 or IL-6, but not IL-1, partially restored Il17 expression in CD4 + T cells activated by p38
DC LCs (Fig. 4F) . Collectively, these data showed that p38 signaling orchestrated a program for LC-dependent IL-17-producing T cell differentiation.
We sought to further assess the functional importance of p38-dependent cytokine production in WT and p38 DC mice treated with IMQ to induce psoriasiform inflammation. Intradermal injection of IL-23 and IL-6, but not IL-1, aggravated the severity of IMQ-induced psoriasiform disease (Fig. 4, G and H, and  fig. S9A ). Injection of either IL-23 or IL-6, but not IL-1, restored ear swelling in p38 DC mice (Fig. 4, G and H, and fig. S9A ). In addition, IL-23 injection completely restored expression of Il17a, Tnfa, Il6, Il1b, Il23a, and Cxcl1 in IMQ-treated p38 DC mice. In contrast, IL-6 and IL-1 restored expression of some cytokines (Fig. 4, I and J, and fig. S9B ). Together, these results showed that p38 mediated the effect on IL-17-producing T cell development and psoriasis pathogenesis through dis tinct cytokines.
We explored the role of p38 signaling in different DC subsets on cytokine production and IL-17-producing T cell development with R848-stimulated dDCs from WT and p38 DC mice. We found that compared with WT dDCs, p38
DC dDCs secreted less IL-6 but com parable IL-23 and IL-1 ( fig. S10A ). Next, we cocultured WT and p38
DC dDCs with  T or naïve CD4 + T cells and found that CD4 + T cells activated by p38 DC dDCs secreted less IL-17, whereas  T cells activated by both WT and p38
DC dDCs expressed comparable levels of IL-17 ( fig. S10, B and C) . Because  T cells are the major IL-17-producing cells that are critical in IMQ-induced psoriasis (5), p38 signaling in different DC subsets instructs IL-17-producing T cell generation and promotes psoriasis pathogenesis through the regulation of IL-23 expression.
IMQ-induced psoriasiform skin disease does not require p38 in T cells
Although p38 signaling in T cells is not required for T H 17 cell differentiation (30), T cell-intrinsic p38 could potentially influence psoriasis pathogenesis by other mechanisms. To evaluate the potential role for T cell-dependent p38 activation in psoriasis, we generated Mapk14 fl/fl CD4-Cre mice [referred to as "p38
T mice" here (30)], which efficiently ablates p38 from T cells ( fig. S11A ). T cell-specific deletion of p38 did not influence the severity or onset of psoriasis as indicated by comparable disease scores, pathological changes, and immune cell recruitment between IMQ-treated WT and p38
T mice (Fig. 5, A to F) . Moreover, genetic abrogation of p38 in T cells did not appreciably affect IL-17 production by  T cells or the expression of Il17a, Tnfa, Il6, Il1b, Il23a, and Cxcl1 in the skin (fig. S11 , B and C). Thus, our results demonstrate that p38 signaling in T cells does not affect IL-17-producing T cell generation or psoriasis development. 
of 11
Inhibition of p38 ameliorates psoriasiform skin disease To evaluate p38 as a potential therapeutic target for the treatment of psoriasis, we examined whether inhibition of p38 activity can alleviate psoriasiform inflammation. When the p38 inhibitor SB203580 was injected into mice that had been previously treated with IMQ, we found that these mice had markedly diminished ear swelling and lower psoriasis disease scores than vehicle-treated mice (Fig. 6A) . Histological analysis showed that the skin of SB203580-treated mice had substantially less epidermal hyperplasia and inflammation than vehicle-treated mice (Fig. 6B) . The infiltration of neutrophils and macrophages into the epidermis and dermis was also reduced in SB203580-treated mice (Fig. 6, C to F) . Moreover, the skin tissues from SB203580-treated mice had lower expression of Il17a, Tnfa, Il6, Il1b, Il23a, and Cxcl1 compared with vehicle-treated mice (Fig. 6G) . However, the expression of Il10 and Tgfb1 in skin tissue was not affected by SB203580 treatment (Fig. 6G) . IL-17 production by CD4 + and  T cells was also decreased in the DLNs of SB203580-treated mice, whereas the frequencies of IFN + and Foxp3 + CD4 + T cells were similar between the two groups ( fig. S12, A and B) . Because a secondary approach to evaluate whether ablation of p38 signaling can ameliorate established psoriatic disease, we administered tamoxifen to WT and p38
CreER mice to acutely ablate p38 expression on days 5 to 8 post-IMQ exposure. Consistent with our SB2034580 treatment results, we observed substantial reductions in ear swelling, composite psoriasis score, neutrophil infiltration, the production of IL-17 from CD4 + and  T cells, and the frequency of IFN + CD4 + T cells in the DLNs in tamoxifen-treated p38 CreER mice ( fig. S13, A to C) . The frequency of Foxp3 + CD4 + T cells was similar in the DLNs from tamoxifentreated WT and p38
CreER mice ( fig. S13C ). These results collectively suggest that inhibition of p38 could offer an approach to treat psoriasis and other inflammatory skin diseases.
DISCUSSION
Although mounting evidence demonstrates essential roles for IL-17-producing T cell-mediated inflammation and DC-T cell cross-talk in the pathogenesis of psoriasis, DC-specific signaling pathways that regulate IL-17-producing T cell responses in the skin still remain poorly defined. Here, we report that p38 signaling in LCs, but not in other DC subsets or T cells, centrally regulated IL-17 production by CD4 + and  T cells in IMQinduced psoriasis model, whereas leaving IFN-, IL-4-, and Foxp3-expressing T cell generation unaffected. p38 activity in LCs differentially promoted IL-17 production from  and CD4 + T cells by secreting IL-23 and IL-6, respectively. Our findings highlight a crucial role for an axis involving p38, IL-23, IL-6, and IL-17-producing T cells in psoriasis and suggest that targeting p38 signaling in LCs may provide an attractive treatment for inflammatory skin disease.
The success of IL-17 blockade in the treatment of psoriasis patients underscores the central role of this cytokine in the pathophysiology of psoriasis (9) . IL-17 can be secreted by multiple cell types, including CD4 + (T H 17), CD8 + (Tc17),  + T cells, innate lymphocytes, and neutrophils (36) . The cytokines IL-1, IL-6, IL-23, and TGF (transforming growth factor-) contribute to the differentiation of T H 17 cells (37) (38) (39) , but the importance of these individual cytokines in directing T H 17 cell development in vivo still remains controversial and may vary depending on the disease models, environmental factors, or target organs (40) (41) (42) . Our previous work establishes that p38 signaling in splenic DCs stimulates T H 17 cell differentiation through the production of IL-6, IL-27, and CD86 expression but is dispensable for IL-1 and IL-23 production (30) . In contrast, we showed in the current study that p38 signaling in LCs regulated T H 17 cell differentiation independently of Il27 and CD86 expression (Fig. 4C and fig. S8B ). Furthermore, we discovered that IL-23 production downstream of p38 signaling contributed to LC-mediated regulation of IL-17 production by  T cells. However, p38 was not required for IL-1 and IL-23 production by skin dDCs, which was similar with our previous findings in splenic DCs (30) . Thus, the discrepant regulation of specific cytokines by the same intracellular signaling pathway in splenic DCs or dDCs compared to skin LCs further highlights the functional heterogeneity of DCs.
Further identification of the molecular pathways that underpin the cell-specific regulation inflammatory responses by p38 is needed to unlock the full clinical potential of DC-targeted therapeutics. DCs bridge innate and adaptive immunity by capturing antigens and migrating into lymph nodes to initiate protective immune responses (12) . Although DC numbers are increased in psoriasis lesions, the results from different groups on the roles of DCs in psoriasis pathogenesis are still controversial because of the usages of different triggers, genetic models, and experimental time points (13, 19, 20, 22, (43) (44) (45) (46) (47) (48) . Our BM chimera results demonstrated that p38 signaling in LCs, but not in other dDCs or inflammatory DCs, was crucial for IL-17-producing T cell development and disease pathogenesis. These results provided genetic evidence supporting the idea of a key proinflammatory function of LCs in psoriasis and that p38 signaling could differentially regulate these effects in distinct cell types.
Because p38 plays an important role in the regulation of numerous proinflammatory responses and disease models (26, 49) , p38 has been extensively investigated for the treatment of inflammatory diseases. Although the advance of p38 inhibitors into clinical trials has been halted, further research into the relevant disease mechanisms could improve the clinical development of p38 inhibitors (50) . Our results showing that inhibition of p38 activity after the onset of disease reduced psoriasis disease progression suggest that p38 inhibitors could be effective for IL-17-mediated diseases. Moreover, our results imply that selectively targeting p38 inhibitors to LCs ameliorated psoriasis symptoms, suggesting that new drug-delivery vehicles that target p38 inhibitors to specific tissues or cell types could be a promising strategy for avoiding undesirable side effects (51) . Local delivery of a p38 inhibitor to the lung reduces inflammation and decreases adverse effects by minimizing exposure of the nontarget organs to the drug (52) . Given that current cytokine antagonist biologic treatments are expensive and have considerable adverse side effects (10) , targeted delivery of small-molecule p38 inhibitors might provide a potential opportunity to improve psoriasis treatment. Therefore, understanding p38-dependent regulation of DC functions and subsequent T cell responses might be further exploited for innovative immune therapies.
MATERIALS AND METHODS
Animals
p38
flox and CD11c Cre mice have been described previously (30, 53, 54) . Rosa26-Cre-ER T2 and CD45.1 + mice were provided by B. Su (Shanghai Jiao Tong University School of Medicine, China). CD4-Cre mice were provided by H. Wang (Shanghai Jiao Tong University School of Medicine, China). OT-II mice were purchased from The Jackson Laboratory. C57BL/6 mice were purchased from Shanghai SLAC Laboratory Animal Co., Ltd (Shanghai, China). All mice were backcrossed to C57BL/6 background for at least eight generations. Age-and sex-matched mice at 6 to 10 weeks of age were used for all experiments. WT or Cre + littermate control mice were used where relevant. No adverse effects due to Cre expression itself were observed in vitro and in vivo in these studies. All mice were kept in specific pathogen-free conditions in the Animal Resource Center at Shanghai Jiao Tong University School of Medicine. Animal protocols were approved by Institutional Animal Care and Use Committee of Shanghai Jiao Tong University School of Medicine.
BM chimeras
For BM chimeric experiments, BM cells from WT or p38 DC mice were intravenously transferred into lethally irradiated either WT or p38 DC mice (5 × 10 6 BM cells per recipient), respectively. Recipient mice were treated with oral antibiotics for 2 weeks after transplantation.
In vivo tamoxifen treatment WT and p38
CreER mice were intraperitoneally injected with 2 mg of tamoxifen (Sigma-Aldrich) per mouse for three consecutive days and then rested for 7 days before experiments.
IMQ-induced mouse psoriasiform skin disease model
A cream containing 5% IMQ (3M Pharmaceuticals or MedShine) providing a dose of 25 mg, or control Vaseline (Fagron), was topically applied to the ear of each mouse daily for six consecutive days. Ear thickness was measured daily using a micrometer, and skin inflammation was scored on day 6 on the basis of the extent and severity of erythema, scaling, and thickening according to the clinical psoriasis area and severity index as previously described (18) . Briefly, the score was determined as follows: 0 = none, 1 = slight, 2 = moderate, 3 = marked, and 4 = very marked. Erythema, scaling, and thickening were scored independently, and the cumulative score served as the disease severity score (scale, 0 to 12). In some experiments, IMQ-treated mice were intradermally injected with recombinant IL-23 (R&D Systems), IL-6 (BD Biosciences), or IL-1 (R&D Systems) at a dose of 50 ng in 20 l of phosphate-buffered saline (PBS) per ear on days 0, 2, and 4. Control mice were injected with the same volume of PBS with 0.1% bovine serum albumin (w/v) on the same schedule.
Pharmacological inhibition of p38
IMQ-treated WT mice were intraperitoneally administrated with p38 inhibitor SB203580 (Merck Calbiochem) at a dose of 0.75 mg/kg body weight from days 3 to 5. Liquid SB203580 dissolved in dimethyl sulfoxide (DMSO; MP Biomedicals) was diluted with PBS for injection into mice. The same volume of DMSO was diluted with PBS for injection into control mice.
Skin cell preparation
Mouse ear skin samples were collected and split into dorsal and ventral halves, and then the subcutaneous fat tissue was carefully scraped off and ears were floated split side down for 40 min at 37°C on the surface of 0.5% trypsin (w/v) (Gibco). The dermis was separated from the epidermis. Each sheet was cut into small pieces and placed into digestion solution containing collagenase IV [1.5 mg/ml (for dermis) or 1 mg/ml (for epidermis); Gibco]. Digestion was performed for 90 min (for dermis) or 80 min (for epidermis) at 37°C with brief mixing. After the digestion, the solution was mixed thoroughly and filtered through a nylon filter to obtain single-cell suspension.
Cell purification, cultures, and DC cytokine assays Epidermal LCs,  T cells, and naïve CD4 + T cells were enriched with microbeads (Miltenyi Biotec) and sorted with a BD FACSAria III sorter. For LC- T cell coculture, LCs from naïve WT and p38 DC mice and  T cells from WT mice were mixed in the presence of R848 (1 g/ml) (InvivoGen). After 48 hours, culture supernatants were collected for ELISA measurements. For LC-CD4 + T cell coculture, LCs from either naïve or IMQ-treated WT and p38 DC mice and naïve CD4 + T cells from OT-II mice were mixed in the presence of ovalbumin peptide (10 g/ml) (OVA 323-339 ) and R848 (1 g/ml). After 5 days, live T cells were harvested and stimulated with PMA (phorbol 12-myristate 13-acetate; Sigma-Aldrich) and ionomycin (Sigma-Aldrich) in the presence of protein transport inhibitor (BD Biosciences) for 5 hours for intracellular cytokine staining, or with plated-bound -CD3 (2C11; Bio X Cell) for 5 hours to measure mRNA expression. In some experiments, recombinant IL-23 (20 ng/ml) (R&D Systems), IL-1 (R&D Systems), or IL-6 (BD Biosciences) cytokines were added to the coculture systems. For DC cytokine assays, LCs from naïve or IMQtreated WT and p38 DC mice were stimulated with R848 (1 g/ml) either for 5 hours before RNA analysis or for 24 hours before ELISA measurement. 
Flow cytometry
Histopathological analysis
Formalin-preserved mouse ear sections were embedded in paraffin according to standard techniques. Longitudinal sections (6 m thick) were stained with hematoxylin and eosin and analyzed by microscopic examination.
Protein and RNA analyses
For cytokine detection in skin tissue, 45-mg skin tissue was weighted and homogenized in 0.5-ml ice-cold CelLytic MT Cell Lysis reagent (Sigma-Aldrich). Concentrations of IL-17, TNF, IL-23, IL-6, and IL-1 in homogenized or culture supernatants were measured by ELISA according to the manufacturer's instructions (eBioscience). Total RNA of skin tissue and cells was isolated using the TRIzol reagent (Invitrogen) and RNeasy Mini Kit (Qiagen), respectively. Reverse transcription was performed via PrimeScript RT Master Mix (Takara) according to the manufacturer's instructions. Quantitative polymerase chain reaction (PCR) was carried out with SYBR Green PCR Master Mix (Applied Biosystems) in a Vii7 Real-Time PCR system (Applied Biosystems). Relative mRNA levels were determined with hypoxanthine-guanine phosphoribosyltransferase (HPRT) as a reference gene. The following primers sequences were used: Hprt, TCAGTCAACGGGGGACATAAA (forward) and GGGGCTGTACTGCT-TAACCAG (reverse); Il17a, TCAGCGTGTCCAAACACTGAG (forward) and CGCCAAGGGAGTTAAAGACTT (reverse); Tnfa, CAGGCG-GTGCCTATGTCTC (forward) and CGATCACCC CGAAGTTCAGTAG (reverse); Il6, CTGCAAGAGACTTCCATCCAG (forward) and AGT-GGTAT AGACAGGTATGTTGG (reverse); Il1b, GCAACTGTTCCT-GAACTCAACT (forward) and ATCTTTTGGGGTCCGTCAACT (reverse); Il23a, GCCCCGTATCCAGTGTGA (forward) and GCT-GCCACTGCTGACTAG (reverse); Csf2, GGCCTTGGAAGCAT-GTAGAGG (forward) and GGAGAACTCGTTAGAGACGACTT (reverse); Cxcl1, TGCACCCAAACCGAAGTCAT (forward) and TTGTCAGAAGCCAGCGTTCAC (reverse); Ifng, GCCACGGCA-CAGTCATTGA (forward) and TGCTGATGGCCTGATTGTCTT (reverse); Il12a, CAATCACGCTACCTCCTCTTTT (forward) and CAGCAGTGCAGGAATAATGTTTC (reverse); Il4, GGTCTCAAC-CCCCAGCTAGT (forward) and GCCGATGATCTCTCTCAAGT-GAT (reverse); Il10, CTTACTGACTGGCATGAGGATCA (forward) and GCAGCTCTAGGAGCATGTGG (reverse); Tgfb1, CTCCCGT-GGCTTCTAGTGC (forward) and GCCTTAGTTTGGACAGGATCTG; Foxp3, CACCTATGCCACCCTTATCCG (forward) and CATGC-GTAAACCAATGGTAGA (reverse); Il22, ATGAGTTTTTCCTTAT-GGGGAC (forward) and GCTGGAAGTTTGGACACCTCAA (reverse); S100a7a, TGCTCTTGGATAGTGTGCCTC (forward) and GCTCTGTGATGTAGTATGGCTG (reverse); S100a8, TGTCCT-CAGTTTGTGCAGAATATAAA (forward) and TCACCATCGCAAG-GAACTCC (reverse); Krt16, GGTGGCCTCTAACAGTGATCT (forward) and TGCATACAGTATCTGCCTTTGG (reverse); Krt17, ACCATCCGCCAGTTTACCTC (forward) and CTACCCAGGC-CACTAGCTGA (reverse); Il27, CTGTTGCTGCTACCCTTGCTT (forward) and CACTCCTGGCAATCGAGATTC (reverse); and Mapk14, GAGGTGCCCGAACGATAC (forward) and TGGCGT-GAATGATGGACT (reverse).
Statistical analysis
The data were analyzed with GraphPad Prism 5 or SPSS 17.0 and are means ± SEM. Analysis of variance (ANOVA) with Bonferroni post test was used for multiple comparisons, and Student's t test was used when two conditions were compared. P values were indicated, and P < 0.05 was considered significant. Two-sided Student's t tests and one-way or two-way ANOVA was performed. ns indicates no significance. Error bars represent SEM.
SUPPLEMENTARY MATERIALS
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